0.9524
price up icon4.11%   0.0372
 
loading
Schlusskurs vom Vortag:
$0.9152
Offen:
$0.8956
24-Stunden-Volumen:
222.94K
Relative Volume:
0.30
Marktkapitalisierung:
$115.98M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-0.3123
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+8.45%
1M Leistung:
-17.86%
6M Leistung:
-57.27%
1J Leistung:
-88.27%
1-Tages-Spanne:
Value
$0.8956
$0.9988
1-Wochen-Bereich:
Value
$0.8471
$0.9988
52-Wochen-Spanne:
Value
$0.7535
$8.58

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
Firmenname
Rapt Therapeutics Inc
Name
Telefon
(650) 489-9000
Name
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
68
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
RAPT's Discussions on Twitter

Vergleichen Sie RAPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RAPT
Rapt Therapeutics Inc
0.9524 115.98M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.04 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.57 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
651.26 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
260.00 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.82 26.40B 3.81B -644.79M -669.77M -6.24

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-26 Hochstufung H.C. Wainwright Neutral → Buy
2024-11-13 Herabstufung Stifel Buy → Hold
2024-11-11 Herabstufung JP Morgan Neutral → Underweight
2024-11-11 Herabstufung Piper Sandler Overweight → Neutral
2024-05-14 Herabstufung Wolfe Research Outperform → Peer Perform
2024-05-10 Herabstufung Barclays Overweight → Equal Weight
2024-05-10 Herabstufung Guggenheim Buy → Neutral
2024-02-22 Herabstufung UBS Buy → Neutral
2024-02-21 Herabstufung H.C. Wainwright Buy → Neutral
2024-02-21 Herabstufung JP Morgan Overweight → Neutral
2024-02-21 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-02-16 Eingeleitet Evercore ISI Outperform
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-09-14 Eingeleitet Berenberg Buy
2023-08-09 Eingeleitet Stifel Buy
2023-06-15 Eingeleitet Barclays Overweight
2023-01-04 Eingeleitet Guggenheim Buy
2022-12-01 Eingeleitet Goldman Buy
2022-09-21 Eingeleitet CapitalOne Overweight
2022-05-24 Fortgesetzt Cantor Fitzgerald Overweight
2021-12-09 Eingeleitet JP Morgan Overweight
2021-08-12 Eingeleitet SVB Leerink Outperform
2021-06-21 Eingeleitet Piper Sandler Overweight
2020-06-01 Eingeleitet H.C. Wainwright Buy
2020-05-19 Eingeleitet Cantor Fitzgerald Overweight
2020-04-13 Eingeleitet ROTH Capital Buy
2019-11-25 Eingeleitet BMO Capital Markets Outperform
2019-11-25 Eingeleitet UBS Buy
2019-11-25 Eingeleitet Wells Fargo Outperform
Alle ansehen

Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten

pulisher
10:25 AM

There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News

10:25 AM
pulisher
May 01, 2025

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX

May 01, 2025
pulisher
May 01, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World

May 01, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 15, 2025

Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World

Apr 13, 2025
pulisher
Mar 20, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 03, 2025
pulisher
Feb 27, 2025

RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 23, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 16, 2025

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Feb 16, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

Feb 14, 2025
pulisher
Feb 12, 2025

Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter

Feb 12, 2025
pulisher
Feb 11, 2025

FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance

Feb 10, 2025
pulisher
Feb 08, 2025

RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex

Feb 04, 2025
pulisher
Jan 29, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 28, 2025

SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow

Jan 28, 2025
pulisher
Jan 26, 2025

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN

Jan 26, 2025
pulisher
Jan 25, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World

Jan 25, 2025
pulisher
Jan 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World

Jan 14, 2025

Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$72.51
price down icon 0.01%
$21.58
price up icon 2.96%
$32.56
price up icon 0.06%
$29.24
price up icon 18.78%
$105.61
price up icon 3.06%
biotechnology ONC
$256.40
price up icon 0.63%
Kapitalisierung:     |  Volumen (24h):